A Phase I Clinical Trial of Ganetespib (Heat Shock Protein 90 Inhibitor) in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2018
Price : $35 *
At a glance
- Drugs Ganetespib (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2018 Status changed from active, no longer recruiting to completed.
- 04 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.